Journal Watch · European Heart Journal · 2026

Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.

Imidazole propionate may refine risk stratification for personalized secondary prevention strategies.

Wenzl FA, Wang P, Kahles F et al.European Heart Journal4 min readPharma relevance 75/100

DOI: 10.1093/eurheartj/ehaf661PMID: 40884168Study type: cohort / observational clinical study

TL;DR

Imidazole propionate may refine risk stratification for personalized secondary prevention strategies.

Key findings

  • Imidazole propionate provided predictive value beyond trimethylamine N-oxide (Swiss ACS cohort: HR 1.30, 95% CI 1.05-1.61, P = .014; German CCS cohort: HR 1.31, 95% CI 1.12-1.53, P = .001).<h4>Conclusions</h4>Gut microbiota-derived ImP predicted MACE in patients with CAD independently of traditional risk factors and holds promise as a therapeutic target.
  • Imidazole propionate may refine risk stratification for personalized secondary prevention strategies.

Numbers at a glance (from the abstract)

n = 4787,n = 150,n = 1428n = 70195%HR 2.34HR 1.32HR 1.34HR 2.38HR 1.50HR 1.30HR 1.31

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Major adverse cardiovascular events (MACE), defined as the first occurrence of a composite of death, non-fatal myocardial infarction, or non-fatal stroke after admission, were the primary endpoint. Cox models, accounting for established risk factors including the gut-derived cardiovascular risk factor trimethylamine N-oxide, were used to evaluate the predictive value of ImP.<h4>Results</h4>Circulating ImP was associated with more advanced CAD and with cardiometabolic characteristics including diabetes and elevated high-sensitivity C-reactive protein. High ImP was an independent predictor of MACE [Swiss ACS cohort: hazard ratio (HR) per log2 increase 1.22, 95% confidence interval (CI) 1.10-1.35, P < .001; German ACS cohort: HR 2.34, 95% CI 1.46-3.76, P < .001; German CCS cohort: HR 1.32, 95% CI 1.13-1.53, P < .001)] and of mortality (Swiss ACS cohort: HR 1.34, 95% CI 1.17-1.54, P < .001; German ACS cohort: HR 2.38, 95% CI 1.48-3.82, P < .001; German CCS cohort: HR 1.50, 95% CI 1.14-1.98, P = .004) after adjustment for established risk factors.

Full abstract (original)

Background: <h4>Background and aims</h4>The gut microbiota is a modulator of cardiometabolic disease. Circulating imidazole propionate (ImP) is a microbiota-derived proatherogenic amino acid metabolite modulating the inflammatory response of myeloid cells, endothelial function, and glucose metabolism. This study examined the prognostic value of ImP in patients with coronary artery disease (CAD).<h4>Methods</h4>Circulating ImP levels were measured in independent prospective cohorts of patients with acute coronary syndrome (ACS; Swiss ACS cohort n = 4787, Swiss cardiac magnetic resonance imaging cohort n = 150, German ACS cohort n = 1428) and chronic coronary syndrome (CCS; German CCS cohort n = 701).

What they did: Major adverse cardiovascular events (MACE), defined as the first occurrence of a composite of death, non-fatal myocardial infarction, or non-fatal stroke after admission, were the primary endpoint. Cox models, accounting for established risk factors including the gut-derived cardiovascular risk factor trimethylamine N-oxide, were used to evaluate the predictive value of ImP.<h4>Results</h4>Circulating ImP was associated with more advanced CAD and with cardiometabolic characteristics including diabetes and elevated high-sensitivity C-reactive protein. High ImP was an independent predictor of MACE [Swiss ACS cohort: hazard ratio (HR) per log2 increase 1.22, 95% confidence interval (CI) 1.10-1.35, P < .001; German ACS cohort: HR 2.34, 95% CI 1.46-3.76, P < .001; German CCS cohort: HR 1.32, 95% CI 1.13-1.53, P < .001)] and of mortality (Swiss ACS cohort: HR 1.34, 95% CI 1.17-1.54, P < .001; German ACS cohort: HR 2.38, 95% CI 1.48-3.82, P < .001; German CCS cohort: HR 1.50, 95% CI 1.14-1.98, P = .004) after adjustment for established risk factors.

Results & conclusions: Imidazole propionate provided predictive value beyond trimethylamine N-oxide (Swiss ACS cohort: HR 1.30, 95% CI 1.05-1.61, P = .014; German CCS cohort: HR 1.31, 95% CI 1.12-1.53, P = .001).<h4>Conclusions</h4>Gut microbiota-derived ImP predicted MACE in patients with CAD independently of traditional risk factors and holds promise as a therapeutic target. Imidazole propionate may refine risk stratification for personalized secondary prevention strategies.

Abstract © the authors / European Heart Journal (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/eurheartj/ehaf661 · PubMed 40884168.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking European Heart Journal for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this European Heart Journal study find?

Imidazole propionate may refine risk stratification for personalized secondary prevention strategies.

What type of study is this?

It is a cohort / observational clinical study, published in European Heart Journal in 2026. Major adverse cardiovascular events (MACE), defined as the first occurrence of a composite of death, non-fatal myocardial infarction, or non-fatal stroke after admission, were the primary endpoint.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/eurheartj/ehaf661. PubMed ID: 40884168. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wenzl FA, Wang P, Kahles F et al.. Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease.. European Heart Journal (2026). DOI: 10.1093/eurheartj/ehaf661.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/gut-microbiota-derived-imidazole-propionate-predicts-cardiometabolic-ris-haf661/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides